HCCC investigates hair regrowth company director

THE director of a hair regrowth company has been banned from selling prescription and pharmacy-only medication to his clients following an investigation by the NSW Health Care Complaints Commission (HCCC).

The investigation found that Samuel Cohen, director of the Institute of Hair Regrowth and Beauty, had supplied clients with medication obtained from other clients’ prescriptions.

The investigation was launched following a complaint to the HCCC from one of Mr Cohen’s clients that he had paid $3,700 for a hair regrowth treatment program that resulted in an allergic reaction.

The HCCC found that Mr Cohen had recommended the drug Loniten to his clients as an approved medication in Australia for hair regrowth. The use of Loniten tablets to promote hair growth is not approved by the Therapeutic Goods Administration (TGA).

Mr Cohen was also found to have recommended topical solutions to his clients involving a combination